Laboratory Corp. of America (NYSE:LH) had its price objective lifted by Mizuho from $150.00 to $174.00 in a research note issued to investors on Monday morning, The Fly reports. They currently have a neutral rating on the medical research company’s stock.

Other analysts also recently issued research reports about the stock. Jefferies Financial Group raised shares of Laboratory Corp. of America from a hold rating to a buy rating and lifted their price target for the company from $154.00 to $190.00 in a research note on Tuesday, April 2nd. Citigroup lifted their price target on shares of Laboratory Corp. of America from $157.00 to $176.00 and gave the company a neutral rating in a research note on Wednesday, May 1st. Zacks Investment Research downgraded shares of Laboratory Corp. of America from a buy rating to a hold rating in a research note on Wednesday, May 15th. TheStreet raised shares of Laboratory Corp. of America from a c+ rating to a b- rating in a research note on Friday, May 3rd. Finally, ValuEngine downgraded shares of Laboratory Corp. of America from a hold rating to a sell rating in a research note on Thursday, April 18th. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and eleven have issued a buy rating to the company’s stock. The company presently has a consensus rating of Hold and an average target price of $179.33.

Shares of NYSE:LH opened at $165.59 on Monday. Laboratory Corp. of America has a 1 year low of $119.38 and a 1 year high of $190.35. The company has a market cap of $16.19 billion, a price-to-earnings ratio of 15.03, a price-to-earnings-growth ratio of 1.70 and a beta of 1.15. The company has a quick ratio of 1.05, a current ratio of 1.14 and a debt-to-equity ratio of 0.77.

Laboratory Corp. of America (NYSE:LH) last announced its earnings results on Tuesday, April 30th. The medical research company reported $2.62 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.53 by $0.09. Laboratory Corp. of America had a return on equity of 16.59% and a net margin of 8.59%. The business had revenue of $2.79 billion during the quarter, compared to analyst estimates of $2.82 billion. During the same quarter in the previous year, the business earned $2.78 earnings per share. The company’s revenue for the quarter was down 2.0% compared to the same quarter last year. Analysts anticipate that Laboratory Corp. of America will post 11.27 EPS for the current fiscal year.

In related news, Director Robert E. Mittelstaedt, Jr. sold 3,700 shares of the business’s stock in a transaction that occurred on Friday, May 3rd. The shares were sold at an average price of $166.30, for a total value of $615,310.00. Following the completion of the transaction, the director now owns 18,909 shares of the company’s stock, valued at $3,144,566.70. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Lisa J. Uthgenannt sold 4,000 shares of the business’s stock in a transaction that occurred on Thursday, May 2nd. The stock was sold at an average price of $164.00, for a total transaction of $656,000.00. Following the completion of the transaction, the insider now directly owns 4,638 shares of the company’s stock, valued at approximately $760,632. The disclosure for this sale can be found here. Insiders sold 8,200 shares of company stock valued at $1,352,410 in the last three months. 0.74% of the stock is currently owned by insiders.

A number of large investors have recently modified their holdings of the stock. Osborn Williams & Donohoe LLC acquired a new position in shares of Laboratory Corp. of America during the first quarter worth $32,000. JFS Wealth Advisors LLC acquired a new position in shares of Laboratory Corp. of America during the fourth quarter worth $26,000. Premia Global Advisors LLC acquired a new position in shares of Laboratory Corp. of America during the first quarter worth $31,000. Bremer Bank National Association acquired a new position in shares of Laboratory Corp. of America during the first quarter worth $35,000. Finally, Evolution Wealth Advisors LLC acquired a new position in shares of Laboratory Corp. of America during the fourth quarter worth $29,000. 91.26% of the stock is owned by institutional investors.

Laboratory Corp. of America Company Profile

Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates in two segments, LabCorp Diagnostics (LCD) and Covance Drug Development. It offers various clinical laboratory tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C and vitamin D products, prostate-specific antigens, tests for sexually-transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests.

Further Reading: What is the downside to momentum investing?

The Fly

Analyst Recommendations for Laboratory Corp. of America (NYSE:LH)

Receive News & Ratings for Laboratory Corp. of America Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Corp. of America and related companies with MarketBeat.com's FREE daily email newsletter.